| For: | Zhang Y, Chung H, Fang QW, Xu YR, Zhang YJ, Nakajo K, Wong ICK, Leung WK, Qiu H, Li X. Current and forecasted 10-year prevalence and incidence of inflammatory bowel disease in Hong Kong, Japan, and the United States. World J Gastroenterol 2025; 31(18): 105472 [PMID: 40496360 DOI: 10.3748/wjg.v31.i18.105472] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v31/i18/105472.htm |
| Number | Citing Articles |
| 1 |
Manjeet Kumar Goyal, Harsh Srivastava, Tanisha Sehgal, Shrinivas Bishu, Vishal Sharma, Shaji Sebastian. Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence. Alimentary Pharmacology & Therapeutics 2026; 63(11) doi: 10.1111/apt.70648
|
| 2 |
Qi Sun, Zhixian Jiang, Lichao Yang, Hao Liu, Peipei Song, Lianwen Yuan. Towards an Asian paradigm of inflammatory bowel disease management: A comparative review of China and Japan. Intractable & Rare Diseases Research 2025; 14(3) doi: 10.5582/irdr.2025.01046
|
| 3 |
Yin Zhang, Xue Li, Qiwen Fang, Deliang Yang, Krishnan Bhaskaran, Angel Y.S. Wong, Wai K. Leung. Association Between Antibiotic Use for Nongastrointestinal Infections and Inflammatory Bowel Disease Flare-Ups: A Self-Controlled Case Series Study. American Journal of Gastroenterology 2026; doi: 10.14309/ajg.0000000000003920
|
| 4 |
Hironori Yamada, Toru Yamada, Shuji Ouchi, Ryota Nakamura, Akiko Tamura, Iichiroh Onishi, Masayoshi Hashimoto, Yoshihiro Moriwaki. Newly Diagnosed Crohn’s Disease After SARS‐CoV‐2 Infection. Case Reports in Gastrointestinal Medicine 2026; 2026(1) doi: 10.1155/crgm/2252518
|
| 5 |
Saleem Ahmad, Muhammad Usman, Maryam Bibi, Muhammad Nauman Aftab, Muhammad Shahbaz Aslam. Small but mighty: the human mycobiome as an immunopharmacological regulator of inflammation and autoimmunity. International Immunopharmacology 2026; 185 doi: 10.1016/j.intimp.2026.116968
|
| 6 |
Layla Ahmed Mohammed Abdelhadi, Nasir A. Ibrahim, Mohammed Osman Abdelrahem Essa, Sheham Guma Ibrahim, Nosiba S. Basher, Hosameldeen Mohamed Husien, Guoqiang Zhu. Adherent-Invasive Escherichia coli (AIEC) in Crohn’s Disease: A Bibliometric Analysis of 25 Years of Research (1999–2025). Microorganisms 2026; 14(6) doi: 10.3390/microorganisms14061183
|
| 7 |
Xiaoran Wang, Nan Zhang, Xiaotong LI, Qiaomei Zhang, Yandi Liu, Hongwen Ma. The impact of nurse-led care in inflammatory bowel disease management: a systematic review. BMC Nursing 2026; 25(1) doi: 10.1186/s12912-026-04678-w
|
| 8 |
Lie Zheng, Sheng-Lei Duan, Kai Wang. Research progress concerning the involvement of the intestinal microbiota in the occurrence and development of inflammatory bowel disease. World Journal of Gastroenterology 2025; 31(42): 113170 doi: 10.3748/wjg.v31.i42.113170
|
| 9 |
Simeng Chen, Qiaozhen Liu, Ning Yu, Rui Fang, Yingxin Zhang, Xi Xu, Jianfa Zhang. A first-in-class orally available DC-SIGN agonist octaparin alleviates TNBS-induced colitis by preserving gut barrier integrity. Biochemical Pharmacology 2026; 250 doi: 10.1016/j.bcp.2026.118083
|
| 10 |
Kui Wang, Yunqing Zeng, Shanshan Zhang, Yanqing Li. Divergent trajectories of inflammatory bowel disease in East, South, South-East and Central Asia: A comprehensive GBD 2021 analysis. Journal of Translational Autoimmunity 2025; 11 doi: 10.1016/j.jtauto.2025.100325
|
| 11 |
Chae Won Cho, Jaewon Roh, Sujeong Lee, Hui Bang Cho, Jungsun Lee, Gyuwon So, Kun Na, Hye Jin Kim, Keun-Hong Park. Orally delivered, pH-resistant dual coated extracellular vesicles restore intestinal barrier function and suppress colitis. Biomaterials 2026; 331 doi: 10.1016/j.biomaterials.2026.124146
|
| 12 |
Ayame Tomii, Chihiro Takei, Keisuke Yoshikiyo, Hidehisa Shimizu. The Gut Microbial Metabolite Indole-3-Acetic Acid Reprograms Systemic Homeostasis and Ameliorates IBD-Associated Cachexia Independent of Food Intake. International Journal of Molecular Sciences 2025; 26(23) doi: 10.3390/ijms262311260
|
| 13 |
Huanyu Li, Chuanyu Zhang, Ziwei Yang, Yifan Li, Dan Liu, Yanan Zhang, Lingmin Zhang, Ning Wang, Mingxin Zhang, Mingzhen Zhang, Zhaoxiang Yu, Xueyong Wei, Yujie Zhang. Engineered prebiotic microcapsules Co-Encapsulating berberine and curcumin Elicit multi-synergistic therapy for ulcerative colitis. Materials Today Bio 2026; 37 doi: 10.1016/j.mtbio.2026.102778
|